Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types

Overexpression of the chondroitin sulfate proteoglycan 4 (CSPG4) has been associated with the pathology of multiple types of such as melanoma, breast cancer, squamous cell carcinoma, mesothelioma, neuroblastoma, adult and pediatric sarcomas, and some hematological cancers. CSPG4 has been reported to...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Immunol
Auteurs principaux: Ilieva, Kristina M., Cheung, Anthony, Mele, Silvia, Chiaruttini, Giulia, Crescioli, Silvia, Griffin, Merope, Nakamura, Mano, Spicer, James F., Tsoka, Sophia, Lacy, Katie E., Tutt, Andrew N. J., Karagiannis, Sophia N.
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2018
Sujets:
Immunology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5767725/
https://ncbi.nlm.nih.gov/pubmed/29375561
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2017.01911
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires